Literature DB >> 28827081

Management of Gastroesophageal Reflux Disease.

C Prakash Gyawali1, Ronnie Fass2.   

Abstract

Management of gastroesophageal reflux disease (GERD) commonly starts with an empiric trial of proton pump inhibitor (PPI) therapy and complementary lifestyle measures, for patients without alarm symptoms. Optimization of therapy (improving compliance and timing of PPI doses), or increasing PPI dosage to twice daily in select circumstances, can reduce persistent symptoms. Patients with continued symptoms can be evaluated with endoscopy and tests of esophageal physiology, to better determine their disease phenotype and optimize treatment. Laparoscopic fundoplication, magnetic sphincter augmentation, and endoscopic therapies can benefit patients with well-characterized GERD. Patients with functional diseases that overlap with or mimic GERD can also be treated with neuromodulators (primarily antidepressants), or psychological interventions (psychotherapy, hypnotherapy, cognitive and behavioral therapy). Future approaches to treatment of GERD include potassium-competitive acid blockers, reflux-reducing agents, bile acid binders, injection of inert substances into the esophagogastric junction, and electrical stimulation of the lower esophageal sphincter.
Copyright © 2018 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antireflux Surgery; Gastroesophageal Reflux Disease; Histamine-2 Receptor Antagonist; Proton Pump Inhibitor

Mesh:

Substances:

Year:  2017        PMID: 28827081     DOI: 10.1053/j.gastro.2017.07.049

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  52 in total

1.  Treatment of Refractory Gastroesophageal Reflux Disease.

Authors:  Rishi D Naik; Matthew H Meyers; Michael F Vaezi
Journal:  Gastroenterol Hepatol (N Y)       Date:  2020-04

Review 2.  The Proton Pump Inhibitor Nonresponder: a Behavioral Approach to Improvement and Wellness.

Authors:  Megan E Riehl; Joan W Chen
Journal:  Curr Gastroenterol Rep       Date:  2018-06-09

Review 3.  Overlap Between GERD and Functional Esophageal Disorders-a Pivotal Mechanism for Treatment Failure.

Authors:  Ofer Z Fass; Ronnie Fass
Journal:  Curr Treat Options Gastroenterol       Date:  2019-03

Review 4.  Advances in the Diagnosis and Treatment of GERD: New Tricks for an Old Disease.

Authors:  Rishi D Naik; Lauren Evers; Michael F Vaezi
Journal:  Curr Treat Options Gastroenterol       Date:  2019-03

5.  Low-Value Proton Pump Inhibitor Prescriptions Among Older Adults at a Large Academic Health System.

Authors:  John N Mafi; Folasade P May; Katherine L Kahn; Michelle Chong; Edgar Corona; Liu Yang; Margaret M Mongare; Vishnu Nair; Courtney Reynolds; Reshma Gupta; Cheryl L Damberg; Eric Esrailian; Catherine Sarkisian
Journal:  J Am Geriatr Soc       Date:  2019-09-05       Impact factor: 5.562

Review 6.  Helicobacter pylori Infection: New Facts in Clinical Management.

Authors:  Peter Malfertheiner; Marino Venerito; Christian Schulz
Journal:  Curr Treat Options Gastroenterol       Date:  2018-12

7.  Why differences between New York and New Delhi matter in approach to gastroesophageal reflux disease.

Authors:  Benjamin D Rogers; C Prakash Gyawali
Journal:  Indian J Gastroenterol       Date:  2019-10

8.  Alginates: From the ocean to gastroesophageal reflux disease treatment.

Authors:  Serhat Bor; İsmail Hakkı Kalkan; Altay Çelebi; Dinç Dinçer; Filiz Akyüz; Peter Dettmar; Hasan Özen
Journal:  Turk J Gastroenterol       Date:  2019-09       Impact factor: 1.852

9.  Ineffective Esophageal Motility in Patients with GERD is no Contraindication for Nissen Fundoplication.

Authors:  Milena Nikolic; Katrin Schwameis; Ivan Kristo; Matthias Paireder; Aleksa Matic; Georg Semmler; Lorenz Semmler; Sebastian F Schoppmann
Journal:  World J Surg       Date:  2020-01       Impact factor: 3.352

Review 10.  Management of Gastroesophageal Reflux Disease in the Elderly Patient.

Authors:  Michael Kurin; Ronnie Fass
Journal:  Drugs Aging       Date:  2019-12       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.